This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/06/15

    Cefaly Technology publishes study in Neurological Sciences of Cefaly nerve stimulation for migraine.

    Cefaly Technology, the creators of the first FDA-approved transcutaneous electrical nerve stimulation device, specifically authorized for use prior to the...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/06/17

    New results with Cefaly external trigeminal nerve stimulation device for migraine published in BMC Neurology- STX-Med

    A new clinical trial reveals that Cefaly, from STX-Med, the first FDA-approved external trigeminal nerve stimulation device for the prevention...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    26/08/15

    New results with Cefaly in migraine pain published in The Journal of Headache and Pain- Cefaly Technologies

    A new study finds that Cefaly, the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for use prior to...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/11/18

    Results of ACME trial of Cefaly with migraine published in Cephalalgia.- STX Medical.

    Cephalalgia, the official peer-reviewed medical journal of the International Headache Society, has just published positive results of the American multicentric...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    12/01/14

    Study shows benefits with Cefaly for Migraine-STX-Med

    A study to determine whether transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly device, from STX-Med, for episodic Migraine prevention,...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/12/21

    Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig as a preventive treatment across the full spectrum of migraine.

    Novartis announced that clinical data for Aimovig (erenumab) was reported in Neurology .

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    11/07/19

    Findings from the from the OVERCOME study showed that nearly 1 in 5 people with migraine (19%) are currently using opioids to treat their disease

    Eli Lilly and Company announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of...

    Journals
    Journal
    31/03/19

    Responsive Neurostimulation for the Treatment of Epilepsy.

    There are a significant number of patients with epilepsy who are drug-resistant and for whom resective procedures are not an option. For these patients, neuromodulation may be an option, including closed-loop stimulation...

    • Source: Neurosurgery Clinics of North America
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/10/12

    Positive results from study of Genesis Neurostimulator (St Jude Medical) in patients with Migraine

    Results from a large-scale study of peripheral nerve stimulation (PNS) of the occipital nerves using the Genesis neurostimulation system, from...

    Blue test tubes arranged in a line, disappearing into the background
    News
    22/10/24

    Emgality demonstrates reduction in frequency, duration, and pain severity in patients with episodic and chronic migraine.- Eli LIlly

    Emgality (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine.

    See more